Suzhou Longbotai Pharmaceutical

Suzhou Longbotai Pharmaceutical is a Chinese biotechnology company focused on the research and development of innovative small molecule drugs for metabolic and endocrine diseases. The company specializes in developing multi-target agonists, particularly those targeting the GLP-1, GIP, and glucagon receptors, to treat conditions such as type 2 diabetes, obesity, and nonalcoholic steatohepatitis (NASH). By leveraging its expertise in medicinal chemistry, Suzhou Longbotai aims to create next-generation metabolic therapies with improved efficacy and safety profiles. The company is headquartered in the Suzhou Industrial Park, a major hub for biopharmaceutical innovation in China.